<DOC>
	<DOCNO>NCT01411137</DOCNO>
	<brief_summary>The purpose study find dos IPX066 require help people Parkinson 's disease compare require carbidopa-levodopa sustained-release tablet ( also know SinemetÂ® CR ) .</brief_summary>
	<brief_title>Carbidopa-Levodopa Extended-Release ( CD-LD ER ) Alone Combination With Carbidopa-Levodopa Immediate Release ( IR ) IPX066 Followed Extension Safety Study IPX066 Subjects With Advanced Parkinson 's Disease</brief_title>
	<detailed_description>Part 1 - This study multicenter open-label study . Subjects convert current treatment IPX066 6-week period . Up 40 subject enrol study . Subjects enter one two cohort . Approximately 24 subject enroll Cohort 1 ( non- Objective Parkinson 's Disease Measurement ( OPDM ) subject ) up-to 16 subject select site enroll Cohort 2 ( OPDM/PK subject ) . Along OPDM measurement , PK blood sample may also collect subject . Part 2 - Following successful completion Part 1 study , eligible subject may participate Part 2 , 6-month open-label extension study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Diagnosed idiopathic PD without know cause Parkinsonism . 2 . At least 30 year old time PD diagnosis . 3 . Currently treat : LD dose frequency least four time day least one dose CDLD ER daily require total daily LD dose least 400 mg stable regimen least 4 week prior Screening 4 . Concomitant therapy amantadine , anticholinergic , selective monoamine oxidase ( MAO ) type B inhibitor ( e.g. , selegiline , rasagiline ) dopamine agonist allow long dos regimens stable least 4 week prior Screening therapy intend constant throughout course study . 5 . Agrees use medically acceptable method contraception throughout study 1 month complete study . 1 . Pregnant breastfeed 2 . Diagnosed atypical Parkinsonism know secondary Parkinsonian syndrome . 3 . Nonresponsive LD therapy . 4 . Prior functional neurosurgical treatment PD ( e.g. , ablation deep brain stimulation ) procedure anticipate study participation . 5 . Planning take participation clinical study : controlledrelease LD product , additional CD benserazide , entacapone tolcapone , nonselective MAO inhibitor , antipsychotic include neuroleptic agent purpose treat psychosis bipolar disorder . 6 . Any evidence suicidal behavior within 6 month enter study . 7 . Allergic hypersensitive CD , LD , entacapone , riboflavin , Yellow Dye # 5 ( tartrazine ) , citrus fruit grape juice . 8 . History currently active psychosis . 9 . Active history peptic ulcer surgical procedure stomach , small intestine large intestine . 10 . Active history narrowangle glaucoma . 11 . History malignant melanoma suspicious undiagnosed skin lesion . 12 . History myocardial infarction residual atrial , nodal , ventricular arrhythmia , upper gastrointestinal hemorrhage , neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis . 13 . Abnormal kidney function 14 . Severe hepatic impairment . 15 . Received investigational medication 4 week prior Screening . 16 . Previously enrol IPX066 study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>